SCHEMBL4233302

SCHEMBL4233302

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(NC(=O)c3ccc(OC45CCCC(CC4)N5C)cc3)cc2)c(F)c1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.38
MCHR1 Q99705 5/20 0.36
NAMPT P43490 1/20 0.36
EPHX2 P34913 3/20 0.36
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MCHR2 Q969V1 1/20 0.35
MET P08581 2/20 0.35
AXL P30530 1/20 0.35
PNLIP P16233 1/20 0.35
BRAF P15056 1/20 0.34
KDR P35968 1/20 0.34
S1PR2 O95136 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4236329 0.92 PKM (0.38) PKMMCHR1NAMPTKDM4EMEN1
SCHEMBL4237744 0.92 PKM (0.38) PKMMCHR1NAMPTKDM4EMEN1
SCHEMBL4238833 0.92 PKM (0.38) PKMMCHR1KDM4EMEN1ALDH1A1
SCHEMBL4237676 0.91 PNLIP (0.41) PKMMCHR1EPHX2KDM4EMEN1
SCHEMBL4229247 0.91 MCHR1 (0.45) PKMMCHR1NAMPTKDM4EMEN1
SCHEMBL4239015 0.91 PKM (0.43) PKMMCHR1NAMPTKDM4EMEN1
SCHEMBL4232012 0.91 EPHX2 (0.39) PKMMCHR1EPHX2KDM4EMEN1
SCHEMBL4237367 0.91 MCHR1 (0.39) PKMMCHR1NAMPTMEN1ALDH1A1
SCHEMBL4235444 0.89 MCHR1 (0.40) PKMMCHR1NAMPTKDM4EALDH1A1
SCHEMBL4787541 0.89 MCHR1 (0.36) PKMMCHR1NAMPTMAPTMCHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP claimed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885MCHR1 47/4885NAMPT 2126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.